CLINICAL_TRIALS
trial_result
· 2024-12-20
Clinical Trial Update: A Dose Ascending Study to Evaluate the Safety of NH002 as a Contrast Agent in Cardiac Echocardiography [Phase 1, Phase 2]
Summary
A dose-ascending Phase 1/2 trial completed to evaluate the safety of NH002 as a contrast agent for cardiac echocardiography, with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Trust Bio-sonics, Inc. | Conditions: Cardiac Disease | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-12-20